The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; EMD Serono; Genentech; Janssen; Pfizer
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer
 
Anthony W. Tolcher
Employment - Next Oncology
Consulting or Advisory Role - AbbVie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); Birdie (Inst); Boston Biomedical (Inst); Eleven Biotherapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forbius (Inst); Genentech/Roche (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); INC Research (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); PSI Pharma Support America (Inst); Ridgeway Therapeutics (Inst); Ryvu Therapeutics (Inst); Scientex (Inst); Seagen (Inst); Sotio (Inst); Symphogen (Inst); Syneos Health (Inst); TFS (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Turning Point Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Ben George
Honoraria - Newlink Genetics
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Cook Medical; Eisai; Exelixis; Foundation Medicine; Ipsen; Merrimack; Taiho Pharmaceutical; TERUMO
Research Funding - Boehringer Ingelheim (Inst); CeGaT (Inst); Celgene (Inst); Eisai (Inst); Foundation Medicine (Inst); Roche (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Araxes Pharma; AstraZeneca; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Takeda; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Susan Elizabeth Moody
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eugene Y. Tan
Employment - Novartis
 
Suman Kumar Sen
Employment - Novartis
 
Dana Peters
Employment - Mirati Therapeutics
 
Xiaohong Yan
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
James G Christensen
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Bluebird Bio; Mirati Therapeutics
Consulting or Advisory Role - BridgeBio Pharma
Patents, Royalties, Other Intellectual Property - Multiple patents in last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors. (Inst)
 
Andrew S. Chi
Employment - Mirati Therapeutics; Neon Therapeutics
Consulting or Advisory Role - Cota Healthcare
Patents, Royalties, Other Intellectual Property - Fused Bicyclic Heterocycles as Therapeutic Agents (Inventor) Provisional Patent Application No. 62/742,041 filed on October 5, 2018
Travel, Accommodations, Expenses - Abbvie
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)